Iceland· IS-EU/1/24/1827/002

Fruzaqla

A fruquintinib product containing fruquintinib, registered in Iceland by Takeda Pharmaceuticals International AG Ireland Branch. The same ATC class is registered in 16 of our 19 countries.

ATC L01EK04

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedFruzaqlaATCL01EK04REGISTER NO.IS-EU/1/24/1827/002PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Fruquintinib is registered in 16 of 19 countries.

Countries holding a registration under ATC L01EK04 (fruquintinib), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 10 of them publish a price we can compare per daily dose

Fruquintinib · ATC L01EK04

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of fruquintinib costs, country by country.

Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Fruquintinib · price per daily dose (3.75 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$189.98
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Fruquintinib
Manufacturer
Takeda Pharmaceuticals International AG Ireland Branch
Country
Iceland (IS)
ATC code
L01EK04
ATC class
Fruquintinib
Defined daily dose
3.75 mg, O
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    505965
    21 stk x1 glas
    ISK 718204

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Fruquintinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fruquintinib products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Fruzaqla
  • Norway · Fruzaqla

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/43c0494f-b56b-4c36-bb19-2220ed77c25c
GET /v1/drugs/43c0494f-b56b-4c36-bb19-2220ed77c25c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Hart hylki",
  "source": "lyfjastofnun",
  "atc_raw": "L01EK04",
  "marketed": true,
  "strength": "5 mg",
  "ma_number": "EU/1/24/1827/002",
  "substance": "Fruquintinib",
  "other_info": "Ávísun lyfsins er bundin við sérfræðinga í krabbameinslækningum.",
  "legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
  "ma_issued_serial": "45463"
}

See everything about fruquintinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.